Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Melinda Fuqua

Nurse Practitioner, Family Terre Haute, IN Nurse Practitioner

NPI 1215223151 CMS profile 11098541

1429 N 6Th St, Terre Haute, IN 47807

Open in the dashboard

General payments

$18,745

391 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Melinda Fuqua of Terre Haute, IN is reported in the CMS Open Payments database as having received $18,745 across 391 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,208 96
2024 General $9,028 107
2023 General $2,406 95
2022 General $952 37
2021 General $1,152 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Melinda Fuqua
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Melinda Fuqua were reported at $5,208. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Melinda Fuqua Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,152 $124 $35–$379 $132
2022 $952 $141 $44–$430 $149
2023 $2,406 $154 $49–$476 $160
2024 $9,028 $165 $51–$504 $164
2025 $5,208 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Phathom Pharmaceuticals, Inc. $8,898 31 payments
  2. AbbVie, Inc. $3,250 120 payments
  3. Janssen Biotech, Inc. $1,774 43 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $775 43 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $691 27 payments
  6. Genzyme Corporation $474 9 payments
  7. Gilead Sciences, Inc. $415 11 payments
  8. Janssen Scientific Affairs, LLC $347 4 payments
  9. QOL Medical, LLC $240 11 payments
  10. Lilly USA, LLC $199 10 payments
  11. Other $1,682 82 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,937 381 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $6,800 7 payments
  3. Travel and Lodging $939 2 payments
  4. Education $69 1 payment
Products named General payments · program years 2021–2025
  1. VOQUEZNA $8,845 29 payments
  2. TREMFYA $1,373 24 payments
  3. RINVOQ $1,312 38 payments
  4. STELARA $1,198 28 payments
  5. SKYRIZI $951 29 payments
  6. XIFAXAN $770 42 payments
  7. HUMIRA $577 21 payments
  8. CREON $475 32 payments
  9. DUPIXENT $474 9 payments
  10. ENTYVIO $451 20 payments
  11. Other $4,330 217 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 43 drugs

Part D claims

2,905

Median for Nurse Practitioner: 389

Drug cost

$2,143,768

Median for Nurse Practitioner: $21,885

Branded share of claims

27.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 70 $554,340
Skyrizi On-Body Risankizumab-Rzaa Brand 23 $456,583
Stelara Ustekinumab Brand 16 $441,533
Xifaxan Rifaximin Brand 56 $185,461
Linzess Linaclotide Brand 154 $150,536
Creon Lipase/Protease/Amylase Brand 22 $82,085
Ibsrela Tenapanor Hcl Brand 23 $61,255
Zenpep Lipase/Protease/Amylase Brand 11 $44,331
Voquezna Vonoprazan Fumarate Brand 44 $29,608
Motegrity Prucalopride Succinate Brand 18 $25,449

The 10 drugs with the highest cost, of 43 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$34,187

Of which drugs: $2,556

Medicare patients

373

Average age 72

Services billed

562

263 women, 110 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 45%
Diabetes 36%
Chronic kidney disease 31%
Depression 31%
COPD 30%
Osteoporosis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 29 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $6,246
$6,246 44 —
STELARA
  • Janssen Biotech, Inc. $285
  • Janssen Scientific Affairs, LLC $160
$445 16 —
TREMFYA
  • Janssen Biotech, Inc. $316
$316 — —
SKYRIZI
  • AbbVie, Inc. $285
$285 23 —
RINVOQ
  • AbbVie, Inc. $246
$246 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 29 with Patron

Records

391 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record